Celularity Inc   (CELU)
Other Ticker:  
Price: $3.4600 $-0.01 -0.288%
Day's High: $3.52 Week Perf: 10.19 %
Day's Low: $ 3.33 30 Day Perf: 12.7 %
Volume (M): 9 52 Wk High: $ 8.90
Volume (M$): $ 31 52 Wk Avg: $3.66
Open: $3.49 52 Wk Low: $1.59

 Market Capitalization (Millions $) 65
 Shares Outstanding (Millions) 19
 Employees 201
 Revenues (TTM) (Millions $) 15
 Net Income (TTM) (Millions $) -181
 Cash Flow (TTM) (Millions $) -37
 Capital Exp. (TTM) (Millions $) 6

Celularity Inc
Celularity Inc. is a biotechnology company based in Warren, New Jersey, United States. It was founded in 2017 by Dr. Robert Hariri and Peter Diamandis with a mission to revolutionize the field of regenerative medicine through the development of innovative cellular therapies. The company focuses on harnessing the power of placental cells to create transformative treatments for a variety of diseases, including cancer, infectious diseases, and autoimmune disorders.

The uniqueness of Celularity comes from its proprietary platform technology, which utilizes placental cells obtained from full-term deliveries. These cells possess a remarkable ability to regenerate tissues and modulate immune responses, making them ideal candidates for therapeutic applications. Celularityes platform technology involves the isolation and characterization of placental cells, including placental hematopoietic stem cells (HSCs) and mesenchymal stem cells (MSCs), which can then be expanded in culture to generate large quantities of cells for therapeutic use.

Celularityes pipeline includes several cellular therapies that are currently in clinical trials or preclinical development. One of its most promising candidates is Cynk-001, an off-the-shelf, allogeneic natural killer (NK) cell therapy derived from placental HSCs. NK cells are a type of immune cell that can directly kill cancer cells and virally-infected cells without prior sensitization, making them ideal for cancer immunotherapy. Cynk-001 has shown great promise in clinical trials for various types of cancer, including multiple myeloma, acute myeloid leukemia, and ovarian cancer.

In addition to cellular therapies, Celularityes platform technology has potential applications in other areas. The company has developed a placental-derived extracellular matrix (ECM) product called Axiologik, which has demonstrated the ability to promote tissue repair and regeneration. Axiologik is being evaluated as a potential treatment for chronic wounds, burns, and other tissue injuries.

Celularity Inc. is a privately-held company that has received significant investment from notable biotech investors, including United Therapeutics Corporation, Sorrento Therapeutics, and Dreyfus Health Foundation. The company has also formed strategic partnerships with other industry leaders, such as United Parcel Service (UPS), for the development of logistics and supply chain solutions for the delivery of cellular therapies.

Overall, Celularity Inc. is a cutting-edge biotech company that is at the forefront of the regenerative medicine field. Its innovative use of placental cells and platform technology has the potential to transform the treatment of a variety of diseases and improve patient outcomes.

   Company Address: 170 Park Ave Florham Park 7932 NJ
   Company Phone Number: 768-2170   Stock Exchange / Ticker: NASDAQ CELU


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Stock Market Announcement

Celularity Inc. Faces Nasdaq Notice for Late Form 10-Q Filing: Impact on Company Shares Assessed

Published Fri, May 24 2024 9:15 PM UTC

In a recent press release, Celularity Inc. (Nasdaq: CELU), a regenerative medicine company focused on developing placental-derived allogeneic cell therapies and advanced biomaterial products, announced its receipt of a notice from the Listing Qualifications department of the Nasdaq Stock Market LLC (Nasdaq). The notification stated that Celularity's failure to file its ...

Product Service News

Placental T Cells Demonstrate Superiority for CAR-T Therapy in the Fight against Cancer

Published Tue, May 14 2024 1:15 PM UTC

CSIMarket.com aims to provide evidence-based research and analysis on the latest advancements in the pharmaceutical industry. In this article, we analyze two key articles to highlight the benefits of placental circulating T cells for CAR-T therapy and discuss Celularity's positive sales expectations for 2024. 1: Celularity Data Published in Journal for ImmunoTherapy of Canc...

Clinical Study

Unleashing the Healing Power: Decellularized Placental Biomaterials for Tendon Injury Management

Published Thu, Apr 18 2024 8:30 PM UTC

Tendon injuries are a significant cause of morbidity and reduced quality of life, affecting millions of people worldwide. Current treatment options often fall short in achieving optimal functional recovery, highlighting the need for innovative approaches. In recent years, emerging technologies in regenerative medicine have shown great promise in addressing the challenges ass...

Management Announcement

Celularity Surpasses Expectations with Strong Net Sales and Implements Promising Strategies for Growth

Published Mon, Apr 15 2024 12:01 PM UTC

Celularity, a leading global biotechnology company specializing in advanced biomaterial products, has recently announced impressive net sales performance for the first quarter of 2024. The company has not only exceeded expectations but also strategized its 2024 selling, general, and administrative (SG&A) reductions, along with a manufacturing ramp. These developmen...

Management Announcement

Celularity's Biovance 3L Receives a Boost with Medicare's Q Code Approval, Revolutionizing Wound Care Treatment

Published Tue, Mar 26 2024 1:01 PM UTC

Celularity, a leading cell therapeutics company, has achieved a significant milestone with the receipt of Healthcare Common Procedure Coding System (HCPCS) Q Code approval from the U.S. Centers for Medicare & Medicaid Services (CMS). This approval establishes Biovance 3L, Celularity's advanced wound care product, as a nationally recognized treatment opt...


Celularity Inc's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com